Investig Clin Urol.  2020 May;61(3):260-268. 10.4111/icu.2020.61.3.260.

Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database

Affiliations
  • 1Department of Urology, Korea University Ansan Hospital, Ansan, Korea
  • 2Department of Urology, Seoul National University Hospital, Seoul, Korea
  • 3Department of Urology, Asan Medical Center, Seoul, Korea
  • 4Department of Urology, Samsung Medical Center, Seoul, Korea
  • 5Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
  • 6Department of Urology, National Cancer Center, Goyang, Korea
  • 7Department of Urology, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea
  • 8Department of Urology, Chonnam National University Hwasun Hospital, Hwasun, Korea
  • 9Department of Urology, Wonkwang University Hospital, Iksan, Korea
  • 10Department of Biostatistics, Soonchunhyang University Seoul Hospital, Seoul, Korea
  • 11Anesthesia Consultants of Indianapolis, Indianapolis, IN, USA

Abstract

Purpose
To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database.
Materials and Methods
Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled. Five-year survival rates were calculated using Kaplan–Meier curve. A clinical calculator for 5-year mortality was developed using multivariable logistic regression analysis and validated externally using dataset including 916 patients from 4 other hospitals.
Results
Overall survival rates and cancer specific survival rate at 5 years were 28.5% and 29.4%, respectively. Among baseline factors, increased neutrophil-lymphocyte ratio (≥4), synchronous metastasis, low albumin (<3.0 g/dL), and low hemoglobin (Conclusions
A clinical calculator has been developed to quantify the risk of death for individual patients after treatment of mRCC. This tool may be useful for patients or their guardians who want to know their prognosis and to identify patients requiring aggressive therapy and additional supportive measures during and after treatment.

Keyword

Carcinoma; Carcinoma, renal cell; Mortality; Prognosis
Full Text Links
  • ICU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr